PharmaResearch Co., Ltd.
214450.KQ - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.2T
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $2.20 Trillion |
|---|---|
| Enterprise Value | $2.20 Trillion |
| Annual dividend | $1100.00 |
| Dividend yield | 0.52% |
| Earnings per Share | $15893 |
| Beta | 0.44 |
| Outstanding Shares | 10,327,000 |
Return
| Return on Equity | 24.64% |
|---|---|
| Return on Assets | 16.77% |
| Return on Invested Capital | 17.96% |
Valuation & Multiples
| P/E Ratio | 11.86 |
|---|---|
| PEG | 61.33 |
| Price to Sales | 3.9 |
| Price to Book Ratio | 2.98 |
| Enterprise Value to Revenue | 3.65 |
| Enterprise Value to EBIT | 12.2 |
| Enterprise Value to Net Income | 11 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.29 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 7, 2026
EPS Estimate
$4043.92
Consensus analyst estimateRevenue Estimate
$174.64 B
Consensus analyst estimateNext Earnings Call
Expected Date
November 6, 2026
EPS Estimate
$3355.05
Consensus analyst estimateRevenue Estimate
$175.74 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About PharmaResearch Co., Ltd.
526 employees
CEO: Jung Sang-soo
PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injec...